{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006473","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.727979+00:00","generated_at":"2026-05-16T03:02:45.423031+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IMDX raises $26M in registered direct offering; funds heart transplant rejection test development","bullets":["Gross proceeds ~$26M from 4,525,976 shares/pre-funded warrants at $5.75/unit; net proceeds ~$24.5M.","Proceeds to expand GraftAssure product line into heart transplant rejection testing, beyond current kidney focus.","Bio-Rad Laboratories, significant shareholder, participated on same terms as other institutional investors.","Offering closed Feb 12, 2026; Lake Street Capital Markets acted as sole placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006473","json":"https://secwatch.observer/filing/0001493152-26-006473.json","markdown":"https://secwatch.observer/filing/0001493152-26-006473.md","text":"https://secwatch.observer/filing/0001493152-26-006473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:02:45.423031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b029335648a8593a550bae6f80deee4e453e1148","claim":"Insight Molecular Diagnostics Inc. entered into Placement Agency Agreement with Lake Street Capital Markets, LLC (effective 2026-02-10).","evidence_excerpt":"The Company entered into a placement agency agreement (the “ Placement Agency Agreement ”), dated as of February 10, 2026, with Lake Street Capital Markets, LLC (the “ Placement Agent ”), pursuant to which the Placement Agent agreed to serve as the placement agent for the Company in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Lake Street Capital Markets, LLC"},{"label":"Effective","value":"2026-02-10"}],"fact_type":"material_agreement"},{"claim_id":"b04a86801415d4f69f1efba799b6fa8b1468d2f9","claim":"Insight Molecular Diagnostics Inc. entered into Purchase Agreements with certain institutional investors valued at approximately $24.5 million (effective 2026-02-10).","evidence_excerpt":"On February 10, 2026, Insight Molecular Diagnostics Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares (the “ Shares ”) of the Company’s common stock, no par value per share (the “ Common Stock ”), and (ii) Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase up to 1,043,478 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) in a registered direct offering (the “ Offering ”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281159), a base prospectus and prospectus supplement relating to the Offering (the “ Prospectus Supplement ”), in each case filed with the Securities and Exchange Commission.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $24.5 million"},{"label":"Effective","value":"2026-02-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}